Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Equity Ratio (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Equity Ratio for 5 consecutive years, with 0.35 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 52.32% to 0.35 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.35 through Dec 2025, down 52.32% year-over-year, with the annual reading at 0.35 for FY2025, 52.32% down from the prior year.
  • Equity Ratio hit 0.35 in Q4 2025 for ARS Pharmaceuticals, down from 0.4 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.99 in Q4 2023 to a low of 0.51 in Q4 2021.
  • Historically, Equity Ratio has averaged 0.62 across 5 years, with a median of 0.93 in 2021.
  • Biggest five-year swings in Equity Ratio: crashed 119.64% in 2022 and later skyrocketed 886.58% in 2023.
  • Year by year, Equity Ratio stood at 0.51 in 2021, then soared by 290.54% to 0.97 in 2022, then increased by 2.06% to 0.99 in 2023, then decreased by 26.1% to 0.73 in 2024, then crashed by 52.32% to 0.35 in 2025.
  • Business Quant data shows Equity Ratio for SPRY at 0.35 in Q4 2025, 0.4 in Q3 2025, and 0.61 in Q2 2025.